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Abstract 1 
Objectives: Tenofovir disoproxil fumarate (TDF) is widely used in the treatment or prevention of HIV 2 
and hepatitis B infection. TDF may cause renal tubulopathy in a small proportion of recipients. We 3 
aimed to study the risk factors for developing severe renal tubulopathy. 4 
Methods: We conducted an observational cohort study with retrospective identification of cases of 5 
treatment-limiting tubulopathy during TDF exposure. We used multivariate Poisson regression 6 
analysis to identify risk factors for tubulopathy, and mixed effects models to analyse adjusted 7 
estimated glomerular filtration rate (eGFR) slopes. 8 
Results: Between October 2002 and June 2013, 60 (0·4%) of 15,983 patients who had received TDF 9 
developed tubulopathy after a median exposure of 44·1 (IQR 20·4, 64·4) months. Tubulopathy cases 10 
were predominantly male (92%), of white ethnicity (93%), and exposed to antiretroviral regimens 11 
that contained boosted protease inhibitors (PI, 90%). In multivariate analysis, age, ethnicity, CD4 cell 12 
count and use of didanosine or PI were significantly associated with tubulopathy. Tubulopathy cases 13 
experienced significantly greater eGFR decline while receiving TDF than the comparator group (-6·60 14 
[-7·70, -5·50] vs. -0·34 [-0·43, -0·26] mL/min/1·73m
2
/year, p<0·0001).  15 
Conclusions: Older age, white ethnicity, immunodeficiency and co-administration of ddI and PI were 16 
risk factors for tubulopathy in patients who received TDF-containing antiretroviral therapy. The 17 
presence of rapid eGFR decline identified TDF recipients at increased risk of tubulopathy. 18 
 19 
  20 
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Introduction 21 
Tenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir (TFV), a nucleotide reverse 22 
transcriptase inhibitor with potent activity against HIV-1 and hepatitis B. Although TDF has a 23 
favourable safety profile, the plasma TFV concentrations obtained with TDF exposure have been 24 
shown to result in a degree of renal tubular dysfunction (1, 2). Manifestations of renal tubular 25 
dysfunction include proteinuria (predominantly low molecular weight proteins) and increased 26 
fractional excretion of phosphate and urate (3). Older age and genetic polymorphisms in the tubular 27 
transporters ABCC2, 4 and 10 (encoding multidrug resistant proteins 2, 4 and 7 respectively) have 28 
been associated with higher TFV concentrations and renal tubular dysfunction (4-9). In cohort 29 
studies, TDF has also been associated with accelerated decline of estimated glomerular filtration 30 
rate (eGFR) and chronic kidney disease (CKD) (10-12). Hence, guidelines suggest that renal function 31 
should be monitored regularly in patients who receive TDF-containing antiretroviral therapy (ART) 32 
(13). 33 
In a small proportion of patients, TDF may cause Fanconi syndrome (a well described proximal renal 34 
tubulopathy, PRT) accompanied by acute tubular injury (ATI) on kidney biopsy (14-24). PRT is 35 
characterised by normoglycaemic glycosuria, proteinuria, renal phosphate wasting and metabolic 36 
acidosis which may be accompanied by reductions in bone mineral density, osteomalacia and/or 37 
fragility fractures (3, 14, 25, 26). The risk factors for developing PRT have not been studied 38 
comprehensively to date. Case reports, case series and a small case-control study have suggested 39 
that older age, immunodeficiency, renal impairment and co-exposure to didanosine (ddI) or boosted 40 
protease inhibitors (PI) may increase the risk of PRT (14-20). The purpose of the present study was to 41 
describe the clinical phenotype of TDF-induced treatment-limiting PRT using the largest cohort of 42 
individuals collected to date, and, using data from the UK CHIC study, analyse the risk factors for 43 
developing renal tubulopathy (PRT/ATI).  44 
Methods 45 
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A multi-centre study was undertaken in HIV clinics which contribute data to the UK CHIC study, a 46 
large multicentre observational cohort study of HIV positive adults in the UK (27). Cases of 47 
treatment-limiting renal tubulopathy were identified retrospectively through searches of electronic 48 
databases and physician recall. Clinical and laboratory data were collected on case report forms. The 49 
study was approved by the National Health Service Research Ethics Committee. 50 
All cases were reviewed by two clinicians (LH and FAP) and included in the analyses if they had 51 
required TDF discontinuation and biochemical evidence of PRT or histological evidence of ATI that 52 
was not explained by other aetiologies (28). PRT was defined by the presence of at least 2 of the 53 
following: normoglycaemic glycosuria (>1+ on dipstick), hypophosphataemia (serum phosphate 54 
<1.98 mg/dl), proteinuria (>1+ on dipstick or protein/creatinine ratio (PCR) >26.5 mg/mg), 55 
hypokalaemia (serum potassium <3·0 mEq/l), and metabolic acidosis (serum bicarbonate <19 mEq/l) 56 
(19). Reductions in eGFR from baseline were not a prerequisite for inclusion in the study. 57 
Comparator subjects were individuals in the UK CHIC study who had attended a centre from which 58 
cases were drawn and who had been exposed to a TDF-containing ART regime without having 59 
developed RT. Follow up was from the date of starting TDF to either the date of stopping TDF or the 60 
last visit (up to 31st December 2013) if TDF was not discontinued. 61 
Baseline variables, including CD4 cell count, HIV viral load (expressed as log10), eGFR (calculated by 62 
CKD-Epi (29)), hepatitis B (HBV surface antigen) and hepatitis C (HCV antibody) status, were defined 63 
as the most recent measurement prior to starting TDF and compared using Chi squared, Fisher’s 64 
exact or Wilcoxon rank sum tests, depending on the variable distribution. Poisson regression analysis 65 
was used to investigate factors associated with renal tubulopathy(30). Age, sex, ethnicity (black vs. 66 
white/other), AIDS, eGFR at start TDF and year of starting TDF were included as fixed covariates, and 67 
hepatitis B and C status, nadir and current CD4 cell count (per 50 cells/mm
3
 increase), HIV RNA (per 68 
1 log10 increase), type of ART regimen (ddI or PI containing/sparing) and time on TDF as time-69 
updated covariates. Factors significant in univariate analysis (p<0·1) were taken forward in the 70 
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multivariable models in a forward stepwise approach. We performed a sensitivity analysis restricted 71 
to individuals with PRT. 72 
We analysed eGFR slopes on TDF in the renal tubulopathy cases and the comparators who had ≥3 73 
eGFR values while receiving TDF using mixed effects models in which time was considered as a 74 
continuous fixed effect (allowing a random intercept for time) and as a random effect (allowing the 75 
slope to vary) (31). Adjusted eGFR slopes were determined using multivariate models; covariates 76 
considered for inclusion included demographic and HIV characteristics, including fixed covariates 77 
such as ethnicity and time updated covariates such as age, PI use, CD4 cell count and viral load. In 78 
additional analyses, the last six months of eGFR results on TDF were excluded to determine if the 79 
mean slope was unduly influenced by eGFR reductions just prior to stopping TDF. Assumptions for 80 
multivariate models were tested graphically. We compared the proportions of subjects with and 81 
without renal tubulopathy who experience rapid eGFR decline (defined as a mean decline in eGFR >3 82 
or >5 ml/min/1·73m
2
/year) or incident CKD while receiving TDF using Chi squared tests. All analyses 83 
were performed using STATA version 12 (StataCorp LP, College Station, Tx). 84 
Results 85 
Baseline characteristics 86 
Between October 2002 and June 2013, 15983 patients received at least four weeks of TDF-87 
containing antiretroviral therapy (ART). During a median follow up of 4·1 (IQR 1·8, 6·7) years, 88 
treatment-limiting renal tubulopathy was diagnosed in 69 (0·4%) subjects, of whom 60 (87%) were 89 
included in the present analyses; 48 met the case definition of PRT and 12 had ATI on renal biopsy 90 
(including four with sufficient data to confirm the presence of PRT). Nine subjects were excluded as 91 
they had <2 markers of PRT and no histological evidence of ATI. 92 
Factors associated with renal tubulopathy 93 
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Renal tubulopathy was diagnosed after a median of 44·1 (IQR 20·4, 64·4 months; range 3·9 months 94 
to 11·0 years) months of TDF exposure. The subjects who were diagnosed with renal tubulopathy 95 
were older at TDF initiation and more likely to be male, of white ethnicity, and to have initiated TDF 96 
in earlier years than those who did not develop renal tubulopathy. The renal tubulopathy cases also 97 
had lower nadir CD4 cell counts, more often a prior AIDS diagnosis, and greater prior ART exposure 98 
at TDF initiation, and they were more likely to have initiated TDF with ddI or a PI. By contrast, 99 
patients with and without renal tubulopathy did not differ by HBV or HCV status, current CD4 cell 100 
count or eGFR at baseline (Table 1). At renal tubulopathy diagnosis, the majority (n=54, 90%) of 101 
patients received an ART regimen that contained a PI [lopinavir (LPV) in 37%, atazanavir (ATV) in 102 
39%, darunavir (DRV) in 13%, other PI in 11% of subjects], and 18 (30%) subjects received ddI (15 as 103 
part of a PI-containing regimen). Normoglycaemic glycosuria was present in 37/46 (80%), 104 
hypophosphataemia in 41/55 (75%), proteinuria in all 55 (100%), hypokalaemia in 3/44 (7%) and 105 
metabolic acidosis in 7/22 (32%) subjects with data. Nine subjects had diabetes mellitus; all diabetics 106 
with glycosuria had a paired plasma glucose measurement within the normal range. In addition, 107 
33/59 patients (56%) had raised serum alkaline phosphatase concentrations (with normal hepatic 108 
transaminases) suggestive of osteomalacia. The median eGFR at renal tubulopathy diagnosis was 109 
52·7 (IQR 44·5, 71·5) mL/min/1·73m
2
, an eGFR reduction of >25% from baseline was observed in 110 
34/57 (60%) of subjects. The clinical characteristics of the PRT and ATI cases were indistinguishable 111 
(Table 2). 112 
In univariate regression analysis, age, gender, ethnicity, CD4 cell count, having initiated TDF in earlier 113 
calendar years and with a more prolonged ART history, and receipt of ddI and PI were associated 114 
with renal tubulopathy (Table 3). Due to interaction between ddI and PI use (p<0·001), ART was 115 
categorised in the model as no ddI/no PI, ddI/no PI, no ddI/PI or ddI/PI. In multivariate analysis, age, 116 
ethnicity, calendar year, CD4 cell count, and ddI and PI use remained significantly associated with 117 
renal tubulopathy (Table 2). Similar results were obtained when the analysis was restricted to the 52 118 
PRT cases (data not shown). The incidence rates of renal tubulopathy on LPV, ATV and DRV were 119 
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similar (0·21 [95% CI: 0·13, 0·32], 0·18 [0·12, 0·27] and 0·10 [0·05, 0·22] per 100 person-years 120 
respectively); the incidence of renal tubulopathy with ATV or DRV did not differ significantly from 121 
LPV (p>0·05 for all). 122 
eGFR slopes on and post TDF 123 
We included 15764 patients in the eGFR slope analysis. In the renal tubulopathy cases, the mean 124 
[95% confidence interval] crude eGFR slope while receiving TDF was -5·55 [-6·47, -4·63] 125 
mL/min/1·73m
2
/year, as compared with -0·19 [-0·24, -0·13] mL/min/1·73m
2
/year in those without 126 
renal tubulopathy (p<0·0001). After adjustment for age, ethnicity and time updated PI use, CD4 cell 127 
count and viral load, the eGFR slopes of subjects who developed renal tubulopathy remained 128 
significantly worse (-6·60 [-7·70, -5·50] vs. -0·34 [ -0·43, -0·26] mL/min/1·73m
2
/year, p<0·0001), even 129 
if eGFR data for the last six months of TDF exposure were excluded (-5·93 [ -7·04, -4·82] vs. -0·22 [-130 
0·30, -0·13] mL/min/1·73m
2
/year, p<0·0001). The mean eGFR slope in the renal tubulopathy cases 131 
improved following TDF discontinuation (+13·21 [9·85, 16·58] during the first six months, +1·26 132 
[0·20, 2·33] mL/min/1·73m
2
/year thereafter). Adverse eGFR patterns were more common among 133 
those who developed renal tubulopathy than those who did not develop renal tubulopathy: rapid 134 
eGFR decline >3 mL/min/1·73m
2
/year was noted in 69·6% and 7·9% (p<0·0001), rapid eGFR decline 135 
>5 mL/min/1·73m
2
/year in 55·4% and 3·5% (p<0·001), and incident CKD (eGFR <60 mL/min/1·73m
2 
136 
for >3 months) in 43·5% and 9·5% (p<0·0001) of patients respectively.  137 
Discussion 138 
This study describes the largest cohort of TDF-associated renal tubulopathy cases to date. Consistent 139 
with previous case series, the majority of patients who developed renal tubulopathy were older, 140 
white men. Renal tubulopathy was associated with TDF use in earlier calendar years when TDF was 141 
more commonly used in PI-containing salvage ART regimens in a setting of limited appreciation of 142 
the potential for renal toxicity and little if any monitoring for renal complications. Many of these 143 
early patients had a history of severe immunodeficiency and prolonged ART exposure; TDF was not 144 
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infrequently co-administered with ddI, and the most commonly used PI in this era was lopinavir, 145 
giving the impression that perhaps this PI predisposed patients to developing renal tubulopathy (19). 146 
The introduction of routine renal monitoring advocated by HIV management guidelines may have 147 
contributed to the decline in the incidence of renal tubulopathy as patients with reduced eGFR were 148 
identified earlier and switched to alternative ART (32). Interestingly, the propensity for TDF to cause 149 
renal tubulopathy appears undiminished as several cases were reported in recent clinical trials in 150 
which patients (with relatively high CD4 cell counts and preserved eGFR) received TDF together with 151 
emtricitabine plus cobicistat/elvitegravir or ritonavir/atazanavir (33, 34). 152 
The pathogenesis of TDF-induced renal tubulopathy remains poorly understood. Proximal tubular 153 
cells are highly metabolically active and renal histology of patients with tubulopathy has revealed 154 
structural abnormalities of mitochondria (14-16). Relatively high CD4 cell counts argue against 155 
opportunistic infection, and given that most cases had an undetectable HIV viral load, a direct action 156 
of HIV appears unlikely. Boosting agents such as ritonavir and cobicistat increase systemic TFV 157 
exposure by approximately 30% (35, 36). Increased TFV exposure and PI co-administration have 158 
been associated with greater eGFR decline (37-39). Organic anion transporters on the basolateral 159 
membrane of proximal tubular cells allow efficient uptake of TFV while ritonavir or cobicistat are 160 
potent inhibitors of apical membrane transporters involved in the extrusion of TFV from these cells; 161 
high intracellular TFV concentration may affect mitochondrial function and thereby the absorptive 162 
capacity of renal tubular cells (40). Of note, particularly high intracellular TFV concentrations have 163 
been reported in a patient with renal tubulopathy (41).  164 
Consistent with previously reported cases (21-24), we observed a strong association between renal 165 
tubulopathy and TDF/ddI co-administration. Exposure to ddI (without TDF or PI) appears to be 166 
sufficient to induce renal tubulopathy (42-45). Didanosine has been shown in vitro to be more toxic 167 
to renal tubular cells than TFV, causing profound depletion of mitochondrial DNA and cytochrome 168 
oxidase II mRNA (46). These effects of ddI were enhanced in the presence of tenofovir, which may 169 
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be the result of TFV-mediated inhibition of purine nucleoside phosphorylase, the enzyme 170 
responsible for ddI phosphorylation and degradation (21, 47).  171 
The majority of our patients who developed renal tubulopathy had received TDF for several years. 172 
Interestingly, the mean eGFR slope during TDF exposure was significantly worse in cases as 173 
compared to comparators, suggesting that sub-clinical renal tubular toxicity had been present 174 
throughout this time. This potentially affords opportunities for early diagnosis. The role of renal 175 
tubular biomarkers has been advocated but their clinical utility remains unclear (48). By contrast, 176 
plasma creatinine and urinalysis for proteinuria and glycosuria are routinely available. Our data 177 
suggest that patients who develop rapid eGFR decline or incident CKD while receiving TDF may be 178 
particularly at risk of developing renal tubulopathy. Such patients should be switched off TDF, or 179 
closely monitored if TDF is continued. The biomarker profile of tenofovir alafenamide (TAF) suggests 180 
that this may be a safer option for such patients (49, 50). 181 
The strong ethnic association observed in this study is consistent with population-specific genetic 182 
susceptibility factors for renal tubulopathy as described for sub-clinical renal tubular dysfunction (4-183 
9). TDF is increasingly used in sub-Saharan Africa where the population is at risk of HIV-associated 184 
nephropathy (HIVAN) (51) and regular monitoring of renal function may not be possible. Our 185 
observation that black patients were at approximately 80% lower risk of developing renal 186 
tubulopathy suggests that severe renal toxicity may be less frequent in this setting, especially if TDF 187 
is used in a relatively young population as part of first line ART that does not include a PI. Of note, no 188 
individuals of black ethnicity in our cohort who received TDF without a PI were diagnosed with 189 
severe tubulopathy.  190 
Strengths and limitations 191 
The strengths of this study include the relatively large number of cases, the robust case definition, 192 
and the large (and for the UK representative) population used to study the risk factors for renal 193 
tubulopathy. However, some limitations need to be acknowledged. Case ascertainment was 194 
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retrospective, which is likely to have resulted in under-ascertainment. The UK CHIC study has limited 195 
information on the reasons for ART discontinuation; some subjects may have been misclassified as 196 
comparators where in fact they discontinued TDF for renal tubulopathy. In addition, there was no 197 
information in the comparator subjects on acute clinical events, concomitant medications such as 198 
nephrotoxic drugs or creatine supplements and other risk factors for renal disease such as 199 
hypertension and diabetes. We were unable to include these in our model and this may have 200 
introduced unmeasured confounding. Our study was also affected by incomplete data which 201 
precluded assessment of the full PRT phenotype in each subject, and nine cases had to be excluded 202 
for insufficient data.   203 
Conclusions 204 
Our study indicates that older age, white ethnicity, immunodeficiency, and co-administration of TDF 205 
with ddI and PI are important risk factors for renal tubulopathy in HIV positive patients. Although 206 
severe renal tubulopathy may manifest within weeks of TDF exposure, the median time to overt 207 
renal toxicity in our patients was more than 3.5 years. Sub-clinical renal tubular dysfunction, as 208 
manifested by rapid eGFR decline or incident CKD, preceded renal tubulopathy in the majority of 209 
patients. Patients who develop these adverse eGFR patterns while receiving TDF should be 210 
considered for alternative therapy or carefully monitored if they are maintained on TDF. With the 211 
availability of tenofovir alafenamide (50, 52), a pro-drug with 90% reduced plasma tenofovir 212 
exposure, the incidence of severe renal tubulopathy is likely to decline. A clinical trial (EudraCT 2016-213 
003345-29) is currently evaluating whether patients with a history of severe renal tubulopathy on 214 
TDF can be safely managed with tenofovir alafenamide (53). 215 
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Table 1: Baseline characteristics of renal tubulopathy cases and controls 
  
RT cases [N=60] Controls [N=15,914] p-value* 
Age [Years] Mean [SD] 45·6 [10·1] 40·7 [9·5] 0·0001 
Sex [Male] N [%] 55 [91·7] 12,689 [79·7] 0·02 
Ethnicity [White/Other] N [%] 56 [93·3] 11,739 [73·8] 0·001 
Exposure [MSM] N [%] 46 [78·9] 9,819 [58·8] 0·06 
Calendar year at TDF start 
 
     
   1996-2003 N [%] 17 [28·3] 1,178 [7·4] <0·0001 
   2004-2007 N [%] 28 [46·7] 5,022 [31·6]  
   2008-2010 N [%] 9 [15·0] 5,014 [31·6]  
   2011-2014 N [%] 6 [10·0] 4,700 [29·5]  
ART naïve at TDF start N [%] 39 [65·0] 9038 [56·8] 0·20 
Years on ART at TDF start Median [IQR] 4·2 [0·0, 7·5] 0·0 [0·0, 5·5] 0·0006 
ddI co-administration N [%] 18 [30] 600 [3·79] <0·0001 
PI co-administration N [%] 37 [61·7] 5,491 [34·5] <0·0001 
Previous AIDS event N [%] 24 [40·0] 4,095 [25·7] 0·01 
HBcAb positive N [%] 3 [8·1] 640 [6·0] 0·60 
HCV Ab positive N [%] 1 [2·9] 1,035 [2·9] 0·22 
Nadir CD4 cell count Median [IQR] 119 [29, 185] 190 [91, 284] 0·0001 
CD4 cell count Median [IQR] 361 [198, 470] 364 [237, 528] 0·37 
HIV RNA [log10 copies] Median [IQR] 2·24 [1·70, 3·44] 2·18 [1·70, 3·13] 0·44 
eGFR [mL/min/1·73m
2
] Mean [SD] 93·6 [16·9] 96·2 [16·4] 0·26 
*level of significance set at p=0·05/15=0·003 
RT: renal tubulopathy, MSM: men who have sex with men, TDF: tenofovir disoproxil fumarate, ART: antiretroviral therapy, 
ddI: didanosine, PI: protease inhibitor, HBV: hepatitis B core antibody, HCV Ab: hepatitis C antibody, eGFR: estimated 
glomerular filtration rate 
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Table 2: Characteristics of PRT and ATI cases 
  
PRT cases [n=48] ATI cases [n=12] P value*  
At baseline      
Age [Years] Mean [SD] 45·8 [10·0] 44·6 [11·0] 0·71  
Sex [Male] N [%] 44 [91·7] 11 [91·7] 0·69  
Ethnicity [White/Other] N [%] 45 [93·8] 11 [91·7] 0·60  
Exposure [MSM] N [%] 37 [77·1] 9 [75·0] 0·84  
Calendar year at TDF start 
 
  0·10  
   1996-2003 N [%] 16 [33·3] 3 [8·3]   
   2004-2007 N [%] 20 [41·7] 7 [66·7]   
   2008-2010 N [%] 6 [12·5] 7 [25·0]   
   2011-2014 N [%] 6 [12·5] 0 [0·0]   
ART naïve at TDF start N [%] 19 [39·6] 2 [16· 7] 0·12  
Years on ART Median [IQR] 3·9 [0·0, 9·3] 4·69 [1·6, 6·5] 0·88  
ddI co-administration N [%] 15 [31·3] 3 [25·0] 0·67  
PI co-administration N [%] 29 [60·4] 8 [66·7] 0·48  
Previous AIDS event N [%] 19 [39·6] 5 [41·7] 0·57  
HBcAb positive N [%] 3 [10·3] 0 [0·0] 0·22  
HCV Ab positive N [%] 1 [3·6] 0 [0·0] 0·80  
Nadir CD4 cell count Median [IQR] 110 [25, 185] 156 [75, 242] 0·32  
CD4 cell count Median [IQR] 317 [169, 459] 470 [335, 635] 0·11  
Viral Load [log10copies] Median [IQR] 2·47 [1·70, 3·57] 1·70 [1·70, 2·36] 0·32  
eGFR [ml/min/1·73m
2
] Mean [SD] 93·1 [17·2] 94·9 [16·5] 0·76  
      
At RT diagnosis      
Duration of TDF exposure months 44·1 43·4 0·39  
PI/r co-exposure N [%] 38 (79·2) 11 (91·7) 0·30  
*level of significance set at p=0·05/15=0·003 
PRT: proximal renal tubulopathy, ATI: acute tubular injury, MSM: men who have sex with men, TDF: tenofovir disoproxil 
fumarate, ART: antiretroviral therapy, ddI: didanosine, PI: protease inhibitor, HBV: hepatitis B core antibody, HCV Ab: 
hepatitis C antibody, eGFR: estimated glomerular filtration rate 
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Table 2: Factors associated with developing renal tubulopathy 
  Univariate Multivariate 
$
 
  RR 95% CI P RR 95% CI P 
Age (per 5 year increase) 1·30 (1·15, 1·47) <0·0001 1·35 (1·19, 1·55) <0·0001 
Sex             
   Male 1           
   Female 0·38 (0·15, 0·94) 0·04    
Ethnicity             
   White/Other 1     1     
   Black 0·21 (0·08, 0·57) 0·002 0·19 (0·07, 0·51) 0·001 
Calendar year at TDF start              
   1996-2003 1        
   2004-2007 0·46 (0·26, 0·81) 0·007 0·78 (0·42, 1·45) 0·43 
   2008-2010 0·31 (0·15, 0·63) 0·001 0·73 (0·29, 1·84) 0·51 
   2011-2014 0·39 (0·15, 0·97) 0·04 1·36 (0·46, 4·03) 0·57 
Antiretroviral naïve at TDF start  1·03 (0·61, 1·76) 0·90       
Time on TDF (per year increase)* 1·08 (0·98, 1·19) 0·13 1·15 (1·03, 1·27) 0·01 
Years on antiretrovirals at TDF start  1·06 (1·00,1·12) 0·03 0·97 (0·91, 1·04) 0·40 
ARV regime*       
No PI / no ddI 1   1   
No PI / ddI 17·62 (6·39, 48·59) <0·0001 17·09 (5·86, 49·84) <0·0001 
PI / no ddI 8·67 (4·01, 18·72) <0·0001 8·87 (4·08, 19·28) <0·0001 
PI / ddI 22·07 (8·88, 54·87) <0·0001 24·57 (9·19, 65·69) <0·0001 
Previous AIDS event  1·48 (0·88, 2·48) 0·14       
Hepatitis B status*              
   Negative 1           
   Positive 1·27 (0·46, 3·53) 0·65       
Hepatitis C status*              
   Negative 1           
   Positive 0·37 (0·09, 1·52) 0·17       
Nadir CD4 cell count (per 50 cell ↓)* 0·89 (0·80, 1·00) 0·05       
CD4 cell count (per 50 cell increase)* 0·91 (0·85, 0·96) 0·001 0·91 (0·86, 0·97) 0·002 
HIV Viral load  (per 1 log increase)* 0·74 (0·44, 1·23) 0·24       
Baseline eGFR (per 10ml/min decrease) 0·90 (0·76, 1·08) 0·26       
*Time updated  
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TDF: tenofovir disoproxil fumarate; ARV: antiretroviral, PI: protease inhibitor, ddi: didanosine, AIDS: acquired immune 
deficiency syndrome, eGFR: estimated glomerular filtration rate; RR: relative risk 
$
 adjusted for fixed covariates: age, ethnicity, years on ARVs prior to TDF start, time updated covariates: DDI use, PI vs. 
NNRTI use, time on TDF and CD4 cell count 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Highlights 
• Severe renal proximal tubulopathy (Fanconi syndrome) was only rarely seen with tenofovir 
disoproxil fumarate (TDF) exposure 
• Being older, of white ethnicity, with more advanced HIV and co-administration of protease 
inhibitors or didanosine increased the risk of developing severe proximal tubulopathy 
• Rapid eGFR decline or incident CKD often preceded overt tubulopapthy and if detected 
should prompt consideration of alternative therapy or careful monitoring if remaining on 
TDF 
